An Unseen Cost of the Ukraine War
Cromos Pharma’s CEO Vlad Bogin was interviewed by Spotlight on America as part of its investigative report on the situation with clinical trials in Ukraine.
Not long-ago Ukraine was a highly attractive location for clinical trials offering numerous distinct advantages for international sponsors including:
- Excellent recruitment potential due to its large population of modern treatment-naïve patients
- Full alignment with EU standards and directives in relation to clinical trials
- A well-organized centralized health system
- Large pool of highly skilled and motivated medical professionals fully compliant with ICH GCP standards
However research in Ukraine has become nearly impossible due to the war, which has already resulted in 200 attacks on medical facilities. The medical infrastructure of Ukraine is being destroyed, which means that potentially life-saving research is being disrupted.
Vlad Bogin was interviewed among other colleagues, Dr. Julie Gralow, the Chief Medical Officer of the American Society of Clinical Oncology, and Ariel Katz, CEO of H1. Each of them claims that the potential that has been developed over the years to conduct successful research in Ukraine has been nearly completely disrupted by the military action.
Cromos Pharma had 12 ongoing clinical trials in Ukraine at the time the war broke out.
“There was a shock, it was completely unexpected,” said Vlad Bogin. “Clearly our initial thoughts were about the people that were in Ukraine, our staff, and we tried to make sure they were safe.”
Since the top priority in any clinical trial conducted by Cromos Pharma is patient safety, the main task of the company’s employees was to track down patients who had fled due to hostilities and help them relocate to a safe place to continue life-saving treatments. One of the most successful operations for Cromos Pharma was tracking down of 58 out of 60 patients participating in a rare cancer trial and allowing them to continue treatment.
The future of clinical trials in Ukraine remains unknown, but Cromos Pharma and its partners do everything possible to ensure the safety of the patients and staff during these hard times.
Please read the story and watch the video here.
Cromos Pharma in Ukraine
Cromos Pharma has been conducting clinical trials in Ukraine since 2006 and established its representative office in Kyiv in 2008. Since then, our highly experienced team in Ukraine has consistently delivered exceptional results for international sponsors.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Turkey to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.
